TAGRISSO 80 MG 28 TB

Tagrisso (osimertinib) is a prescription medication used in the treatment of non-small cell lung cancer (NSCLC) that has certain mutations in the epidermal growth factor receptor (EGFR) gene, particularly the T790M mutation. The product description for Tagrisso 80 mg tablets typically includes information such as:

• Active Ingredient: Each tablet contains 80 mg of osimertinib.
• Indication: Tagrisso is indicated for the treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations.
• Formulation: Tablets for oral administration.
• Packaging: Typically supplied in blister packs containing 28 tablets.
• Mechanism of Action: Tagrisso is a third-generation EGFR tyrosine kinase inhibitor (TKI) that selectively inhibits both EGFR-sensitizing and EGFR T790M resistance mutations.
• Dosage: The recommended dose is usually one 80 mg tablet once daily, with or without food, until disease progression or unacceptable toxicity occurs.